Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Almac and Affymetrix Announce a Global Distribution Agreement for Almac’s Xcel™ Array

Published: Friday, March 30, 2012
Last Updated: Friday, March 30, 2012
Bookmark and Share
Xcel™ array optimized for RNA expression profiling from FFPE samples.

Almac has announced that it has signed an exclusive global distribution deal with Affymetrix, Inc. enabling them to directly sell Almac’s proprietary Xcel™ array for biomarker discovery, development and delivery worldwide.

Almac’s Xcel™ array is a high density transcriptome-based microarray that has been optimized for the discovery and development of biomarkers from formalin fixed paraffin embedded (FFPE) tissue.

Designed by Almac and built on the industry standard Affymetrix’ GeneChip® platform, the content of Xcel™ array has been derived from high quality sequence data, as well as mining public gene expression and sequence databases.

The array contains more content than all currently available 3` microarrays, with over 97,000 transcripts including antisense, non-coding transcripts and significant unique content.

Working with FFPE enables the potential to profile retrospective samples in tissue banks, a highly valuable resource.

Standard practice is to collect patient samples and store in FFPE and the ability to unlock information from these samples will rapidly increase the discovery opportunities in personalized medicine.

Further to this, translating these discoveries into the clinic on an FFPE platform will drive the commercialization of these biomarkers.

The substantial content on Almac’s Xcel™ array ensures that the platform technology is ideally suited for research in cross-disease areas, a notable advantage to pharmaceutical companies.

It has also been designed to include all of the content from the Affymetrix’ GeneChip® Human Genome U133 Plus 2.0 Array, enabling simple transfer and continuation of existing research.

Kevin Cannon, PhD, Expression Business Lead at Affymetrix commented: “Almac’s Xcel™ array with its superior design and content derived from multiple cancer types provides an ideal microarray for gene expression profiling from FFPE tissues, unlocking previously inaccessible genetic content for translational research. Researchers now have the ability to carry out retrospective studies for discovery and validation of gene expression biomarkers and translate them into clinical practices. This array represents a significant technology advancement, and combined with Genisphere’s Sensation™ reagents address a much needed FFPE workflow solution for gene expression profiling and biomarker discovery.”

Vice President of Business Development of Almac’s Diagnostics Business Unit, Michael Sloan commented: “We are very pleased to have entered into this agreement with Affymetrix. The Xcel™ array has proven to be extremely useful in our hands for biomarker discovery both for our in-house R&D and for our clients. This distribution deal with Affymetrix will enable more researchers to see the benefit of the platform.”

Affymetrix will officially launch the Almac Xcel™ array at this year’s AACR annual meeting in Chicago.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac and TTP Labtech form Alliance in Fluorescence Lifetime Technology
This will give customers of either party access to a broad range of biological applications coupled with the next generation of microplate reader technology.
Tuesday, January 08, 2013
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
New Method to Preserve Device to Monitor HIV Treatment
Inspired by pregnancy tests, scientists have developed a method to store microfluidic devices for months without refrigeration, giving developing countries an inexpensive and reliable way to treat patients.
Migration Creates Cancer Cell Vulnerabilities
Scientists found that migration can damage cancer cells’ nuclei and DNA, requiring repairs for their survival. The results may open new avenues for targeting metastatic cancer.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!